A recent study conducted by researchers at Columbia University and NYU College of Dentistry suggests that targeting antidepressants to interact exclusively with intestinal cells could potentially be more effective in treating depression and anxiety while minimizing side effects. The study found that antidepressants like Prozac and Zoloft, which raise serotonin levels, can sometimes cause side effects that patients find intolerable. By restricting the drugs to interact only with intestinal cells, researchers believe they can avoid these issues.
The study also revealed that taking antidepressants during pregnancy can make newborn babies more susceptible to depression for up to a year. By developing antidepressants that increase serotonin levels only in the cells lining the intestines, researchers hope to prevent gastrointestinal complications in babies and improve the mood of depressed patients.
Antidepressants known as selective serotonin reuptake inhibitors (SSRIs) have been the primary treatment for mood disorders and anxiety for the past thirty years. These medications primarily target the brain to increase serotonin signaling, but can also impact the gut's serotonin signaling mechanisms.
Using mice in their study, researchers engineered the guts to increase serotonin signaling, mimicking the effects of an SSRI restricted to the intestines. The mice with increased serotonin signaling in the gut exhibited lower levels of depressive behaviors compared to regular mice. The researchers were surprised by the robust antidepressant and anxiety-relieving effects produced without noticeable side effects.
Overall, the study suggests that SSRIs may work by directly targeting the gut, rather than solely focusing on the central nervous system. By understanding the interactions between the brain and gut, researchers hope to develop more effective antidepressants with fewer side effects.